Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)

Inclusion Criteria

• •Referred patients will initially be consented for procurement of blood for generation of the transduced ATL. Eligibility criteria at this stage include:
• •Diagnosis of recurrent CD30+ HL or CD30+ NHL, or newly diagnosed patients unable to receive or complete standard therapy OR diagnosis of relapsed/refractory CD30+ HL or CD30+ NHL with a treatment plan that will include high dose therapy and stem cell transplantation
• •CD30 positive tumor (result can be pending at this time)
• •Hgb \> 8.0
• •Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.
• •Karnofsky or Lansky score greater than 60%
• •Diagnosis - CD30+ HL or CD30+ NHL:
• •1. During the Dose Escalation Phase: only adult patients with active disease failing standard therapy
• •2. After Dose Escalation: any patient (children or adults) newly diagnosed, unable to receive or complete standard therapy OR diagnosis of relapsed/refractory CD30+ HL or CD30+ NHL with a treatment plan that will include high dose therapy and autologous stem cell transplantation. (During dose escalation: only adult patients (age 18 and older; After Dose Escalation: any patient (children ages 0-17 or adults)
• •* CD30 positive tumor
• •* Bilirubin 1.5 times or less than upper limit of normal.
• •* AST 3 times or less than upper limit of normal.
• •* Serum creatinine 1.5 times or less than upper limit of normal.
• •* Pulse oximetry of \> 90% on room air
• •* Karnofsky or Lansky score of \> 60%.
• •* Available autologous T cells with 15% or more expression of CD30CAR determined by flow-cytometry.
• •* Recovered from acute toxic effects of all prior chemotherapy at least one week and 30 days from prior chemotherapy before entering this study
• •* Adequate pulmonary function with FEV1, FVC and DLCO greater than or equal to 50% of expected corrected for hemoglobin.
• •* Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom.
• •* Patients or legal guardians must sign an informed consent indicating that they are aware this is a research study and have been told of its possible benefits and toxic side effects. Patients or their guardians will be given a copy of the consent form.